Startup Loxo raises $33m to fund cancer drugs, pact with Array
This article was originally published in Scrip
Executive Summary
Loxo Oncology raised $33m in Series A venture capital to finance the development of targeted cancer therapies for genetically defined patient populations based on technology the New York-based company licensed from Array BioPharma in July.